Shufro Rose & Co. LLC lowered its position in Quest Diagnostics Incorporated (NYSE:DGX) by 3.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,515 shares of the medical research company’s stock after selling 350 shares during the period. Shufro Rose & Co. LLC’s holdings in Quest Diagnostics were worth $1,058,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the company. Trillium Asset Management LLC boosted its position in Quest Diagnostics by 3.4% in the second quarter. Trillium Asset Management LLC now owns 133,686 shares of the medical research company’s stock worth $14,861,000 after buying an additional 4,344 shares during the period. Wedbush Securities Inc. boosted its position in Quest Diagnostics by 19.2% in the second quarter. Wedbush Securities Inc. now owns 4,681 shares of the medical research company’s stock worth $520,000 after buying an additional 754 shares during the period. IFC Holdings Incorporated FL bought a new position in Quest Diagnostics during the second quarter worth approximately $202,000. Teacher Retirement System of Texas boosted its position in Quest Diagnostics by 3.9% in the second quarter. Teacher Retirement System of Texas now owns 31,863 shares of the medical research company’s stock worth $3,542,000 after buying an additional 1,200 shares during the period. Finally, DekaBank Deutsche Girozentrale boosted its position in Quest Diagnostics by 25.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 164,990 shares of the medical research company’s stock worth $18,313,000 after buying an additional 33,091 shares during the period. 90.06% of the stock is owned by hedge funds and other institutional investors.

Quest Diagnostics Incorporated (NYSE:DGX) opened at 106.46 on Tuesday. The company has a 50-day moving average price of $108.73 and a 200-day moving average price of $103.30. The firm has a market cap of $14.52 billion, a P/E ratio of 21.46 and a beta of 0.69. Quest Diagnostics Incorporated has a 1-year low of $79.12 and a 1-year high of $112.96.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Tuesday, July 25th. The medical research company reported $1.55 EPS for the quarter, topping the consensus estimate of $1.42 by $0.13. Quest Diagnostics had a return on equity of 15.66% and a net margin of 9.28%. The business had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter last year, the company earned $1.34 EPS. The firm’s revenue was up 1.9% compared to the same quarter last year. On average, equities research analysts forecast that Quest Diagnostics Incorporated will post $5.69 EPS for the current fiscal year.

WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/quest-diagnostics-incorporated-dgx-shares-sold-by-shufro-rose-co-llc/1490434.html.

A number of research firms have commented on DGX. BidaskClub raised shares of Quest Diagnostics from a “sell” rating to a “hold” rating in a research report on Tuesday. Morgan Stanley boosted their target price on shares of Quest Diagnostics from $87.00 to $92.00 and gave the company an “underweight” rating in a research report on Thursday, August 10th. Zacks Investment Research cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Thursday, August 3rd. Bank of America Corporation raised shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $111.00 to $118.00 in a research report on Tuesday, July 25th. Finally, Piper Jaffray Companies boosted their target price on shares of Quest Diagnostics to $107.00 and gave the company a “neutral” rating in a research report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $109.62.

In other Quest Diagnostics news, SVP Catherine T. Doherty sold 59,762 shares of the firm’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $107.55, for a total value of $6,427,403.10. Following the completion of the transaction, the senior vice president now owns 78,582 shares in the company, valued at approximately $8,451,494.10. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey M. Leiden sold 296 shares of the firm’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $106.66, for a total value of $31,571.36. Following the completion of the transaction, the director now owns 6,000 shares of the company’s stock, valued at approximately $639,960. The disclosure for this sale can be found here. In the last 90 days, insiders sold 61,362 shares of company stock valued at $6,600,758. 1.50% of the stock is owned by corporate insiders.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.